BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33677797)

  • 21. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
    Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
    Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
    Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.
    Somaiah N; Tap W
    Cancer Treat Rev; 2024 Jan; 122():102668. PubMed ID: 38104352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of the MDM2/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma.
    Yamashita K; Kohashi K; Yamada Y; Akatsuka S; Ikuta K; Nishida Y; Toyokuni S; Oda Y
    Genes Chromosomes Cancer; 2021 Jan; 60(1):26-37. PubMed ID: 33111425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
    Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
    J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.
    Schöffski P; Lahmar M; Lucarelli A; Maki RG
    Future Oncol; 2023 Mar; 19(9):621-629. PubMed ID: 36987836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
    Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
    Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment and characterization of NCC-MFS3-C1: a novel patient-derived cell line of myxofibrosarcoma.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Sei A; Takeshita F; Sugaya J; Iwata S; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2021 Jul; 34(4):1266-1273. PubMed ID: 33990915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment and characterization of NCC-PLPS2-C1: a novel cell line of pleomorphic liposarcoma.
    Akiyama T; Yoshimatsu Y; Noguchi R; Sin Y; Osaki J; Adachi Y; Ono T; Tsuchiya R; Sato C; Iwata S; Kojima N; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2023 Jan; 36(1):468-475. PubMed ID: 36436139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
    Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM
    J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma.
    Weiss MC; Eulo V; Van Tine BA
    Clin Cancer Res; 2024 Feb; 30(4):649-651. PubMed ID: 38064245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment and characterization of NCC-MPNST6-C1: a novel patient-derived cell line of malignant peripheral nerve sheath tumors.
    Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Ono T; Akiyama T; Nakatani F; Sugaya J; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2022 Jan; 35(1):400-407. PubMed ID: 34775549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment and characterization of NCC-SS4-C1: a novel patient-derived cell line of synovial sarcoma.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Ono T; Sei A; Takeshita F; Sugaya J; Iwata S; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2021 May; 34(3):998-1007. PubMed ID: 33611700
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Casadei L; Calore F; Braggio DA; Zewdu A; Deshmukh AA; Fadda P; Lopez G; Wabitsch M; Song C; Leight JL; Grignol VP; Lev D; Croce CM; Pollock RE
    Cancer Res; 2019 Oct; 79(19):4911-4922. PubMed ID: 31387924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features: a clinicopathological analysis of five cases].
    Si HP; Wang Z; Fan QH; Zhang YF; Yang DQ; Zhang ZH; Gong QX
    Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):282-287. PubMed ID: 30955263
    [No Abstract]   [Full Text] [Related]  

  • 36. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
    Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
    Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
    Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N
    J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of
    Rekhi B; Karnik N; Agrawal R; Shetty O; Patkar S
    Indian J Pathol Microbiol; 2022; 65(1):65-75. PubMed ID: 35074968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment and characterization of NCC-MLPS1-C1: a novel patient-derived cell line of myxoid liposarcoma.
    Noguchi R; Yoshimatsu Y; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2021 Mar; 34(2):667-674. PubMed ID: 33146842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.
    Saâda-Bouzid E; Burel-Vandenbos F; Ranchère-Vince D; Birtwisle-Peyrottes I; Chetaille B; Bouvier C; Château MC; Peoc'h M; Battistella M; Bazin A; Gal J; Michiels JF; Coindre JM; Pedeutour F; Bianchini L
    Mod Pathol; 2015 Nov; 28(11):1404-14. PubMed ID: 26336885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.